Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”

Robert B. Cameron; Jacobi B. Hines; Valter Torri; Marina C. Garassino

doi:10.1016/j.jtho.2024.09.1424

Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”

Robert B. Cameron^*, Jacobi B. Hines, Valter Torri, Marina C. Garassino

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e80-e81
Journal	Journal of Thoracic Oncology
Volume	19
Issue number	12
DOIs	https://doi.org/10.1016/j.jtho.2024.09.1424
State	Published - Dec 2024

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jtho.2024.09.1424

Cite this

Cameron, R. B., Hines, J. B., Torri, V., & Garassino, M. C. (2024). Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”. Journal of Thoracic Oncology, 19(12), e80-e81. https://doi.org/10.1016/j.jtho.2024.09.1424

@article{28fc97a91c7840d98096fc0f5607f7dd,

title = "Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”",

author = "Cameron, {Robert B.} and Hines, {Jacobi B.} and Valter Torri and Garassino, {Marina C.}",

year = "2024",

month = dec,

doi = "10.1016/j.jtho.2024.09.1424",

language = "English (US)",

volume = "19",

pages = "e80--e81",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "12",

}

Cameron, RB, Hines, JB, Torri, V & Garassino, MC 2024, 'Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”', Journal of Thoracic Oncology, vol. 19, no. 12, pp. e80-e81. https://doi.org/10.1016/j.jtho.2024.09.1424

Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”. / Cameron, Robert B.; Hines, Jacobi B.; Torri, Valter et al.
In: Journal of Thoracic Oncology, Vol. 19, No. 12, 12.2024, p. e80-e81.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”

AU - Cameron, Robert B.

AU - Hines, Jacobi B.

AU - Torri, Valter

AU - Garassino, Marina C.

PY - 2024/12

Y1 - 2024/12

UR - http://www.scopus.com/inward/record.url?scp=85209655607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85209655607&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2024.09.1424

DO - 10.1016/j.jtho.2024.09.1424

M3 - Letter

C2 - 39645303

AN - SCOPUS:85209655607

SN - 1556-0864

VL - 19

SP - e80-e81

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 12

ER -

Commentary on “Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC”

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this